Dr. Bang-Andersen graduated from University College London (MSc chemistry) and from the Royal Danish School of Pharmacy (today part of the Faculty of Health and Medical Sciences, University of Copenhagen) (MSc pharmacy), where he also obtained his PhD in Medicinal Chemistry under supervision of Professor Povl Krogsgaard-Larsen. Dr. Bang-Andersen has worked with drug discovery for nearly 30 years, and he has extensive leadership experience as drug discovery project leader, line manager in Research, and as senior scientist in R&D. Dr. Bang-Andersen has led the research toward the nomination of several clinical drug candidates, including the Medicinal Chemistry Team discovering the blockbuster antidepressant vortioxetine (Trade names Brintellix/Trintellix). Dr. Bang-Andersen’s current focus is on molecular imaging, where he is responsible for preclinical molecular imaging, including the discovery and development of novel molecular imaging ligands and technologies to support translation of drug projects from animals to humans.